JAMA Internal Medicine
JAMA Internal Medicine is the JAMA Network's internal-medicine journal, known for sceptical, evidence-based analyses of overdiagnosis, surrogate endpoints and low-value care in cancer.
JAMA Internal Medicine was formerly Archives of Internal Medicine (renamed 2013). It is home to the 'Less Is More' series and of influential critiques of oncology evidence, including Prasad and colleagues' 2015 review of surrogate endpoints in cancer drug approvals, plus prevention studies such as the PREDIMED breast-cancer analysis. Hybrid access.
A drug that shrinks tumours or delays progression on scans has not necessarily been shown to help patients live longer or better. Patients and clinicians should ask what the endpoint was; regulators should insist on timely confirmatory trials; and trialists should validate surrogates before relying on them.
A Mediterranean dietary pattern rich in olive oil may lower breast cancer risk, and it is safe and good for the heart anyway. The evidence is suggestive, not definitive, because of the small number of cancers; it should not be presented as proven cancer prevention.
Nothing links here yet.